WAVE LIFE SCIENCES LTD. Cash and Restricted Cash
WAVE LIFE SCIENCES LTD. (WVE) had Cash and Restricted Cash of $114.10 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-05-09
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $114.10M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $146.11M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133.09M.
- 2016-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $153.89M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-03-31 | $114.10M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $146.11M 10-Q · filed 2018-05-09 |
| 2017-03-31 | $133.09M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $153.89M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |